Cite
Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease.
MLA
Ortiz-Maldonado, Valentín, et al. “Results of ARI-0001 CART19 Cell Therapy in Patients with Relapsed/Refractory CD19-Positive Acute Lymphoblastic Leukemia with Isolated Extramedullary Disease.” American Journal of Hematology, vol. 97, no. 6, June 2022, pp. 731–39. EBSCOhost, https://doi.org/10.1002/ajh.26519.
APA
Ortiz-Maldonado, V., Alonso-Saladrigues, A., Español-Rego, M., Martínez-Cibrián, N., Faura, A., Magnano, L., Català, A., Benítez-Ribas, D., Giné, E., Díaz-Beyá, M., Correa, J. G., Rovira, M., Montoro-Lorite, M., Martínez-Roca, A., Rodríguez-Lobato, L. G., Cabezón, R., Cid, J., Lozano, M., Garcia-Rey, E., … Rives, S. (2022). Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease. American Journal of Hematology, 97(6), 731–739. https://doi.org/10.1002/ajh.26519
Chicago
Ortiz-Maldonado, Valentín, Anna Alonso-Saladrigues, Marta Español-Rego, Nuria Martínez-Cibrián, Anna Faura, Laura Magnano, Albert Català, et al. 2022. “Results of ARI-0001 CART19 Cell Therapy in Patients with Relapsed/Refractory CD19-Positive Acute Lymphoblastic Leukemia with Isolated Extramedullary Disease.” American Journal of Hematology 97 (6): 731–39. doi:10.1002/ajh.26519.